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Abstract: Mutations to the cholesterol transport protein apolipoprotein E (ApoE) have been identified
as a major risk factor for the development of sporadic or late-onset Alzheimer’s disease (AD), with
the e4 allele representing an increased risk and the rare e2 allele having a reduced risk compared
to the primary e3 form. The reasons behind the change in risk are not entirely understood, though
ApoE4 has been connected to inflammation and toxicity in both the brain and the periphery. The
goal of this study was to better understand how the ApoE isoforms (ApoE2/3/4) confer differential
AD-related risk by assessing cell-specific ApoE-related neuroinflammatory and neurotoxic effects.
We compared the effects of ApoE isoforms in vitro on human astrocytes, a human immortalized
microglia cell line (HMC3), and the human neuroblastoma cell line SH-SY5Y. Cells were treated for
24 h with or without recombinant ApoE2, ApoE3, or ApoE4 (20 nM) and inflammation and toxicity
markers assessed. Our results indicated the expression of inflammatory cytokines IL-1β, TNFα,
and IL-6 in human astrocytes was increased in response to all ApoE isoforms, with ApoE4 evoking
the highest level of cytokine expression. In response to ApoE2 or ApoE3, microglial cells showed
reduced levels of microglial activation markers TREM2 and Clec7a, while ApoE4 induced increased
levels of both markers. ApoE2 promoted neuron survival through increased BDNF release from
astrocytes. In addition, ApoE2 promoted, while ApoE4 reduced, neuronal viability. Overall, these
results suggest that ApoE4 acts on cells in the brain to promote inflammation and neuronal injury
and that the deleterious effects of ApoE4 on these cells may, in part, contribute to its role as a risk
factor for AD.
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1. Introduction
The most significant known genetic risk factor for sporadic or late-onset Alzheimer’s
disease (AD) is an allele variant of apolipoprotein E (ApoE), a protein involved in lipid
metabolism and cholesterol homeostasis [1]. The ApoE gene has three polymorphic alleles
that occur in humans, e2, e3, and e4. These alleles occur at different frequencies, with e3
occurring most frequently at 65–70%, followed by e4 and e2 [1]. However, the frequency of
the e4 allele is substantially increased by approximately 40% in AD patients compared to
healthy counterparts [2]. Population studies have shown that the e4 allele is associated with
a significantly elevated likelihood for developing Alzheimer’s, while the e2 variant seems
to have protective effects compared to e3 [1,2]. Although the relationship between ApoE
alleles and AD has been well-established, the mechanisms behind these risk differences
have not been well characterized.
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ApoE is primarily synthesized in the liver, but the brain synthesizes its own ApoE as
well. ApoE mRNA has been found in the cerebral cortex, hippocampus, cerebellum, and
medulla [3]. In the brain, ApoE is synthesized primarily by astrocytes, but is also believed
to be produced by oligodendrocytes, microglia, and neurons under stress conditions [1].
Due to its primary function as a lipid transport molecule, ApoE has largely been studied
for its role in Aβ clearance in AD. ApoE4 impairs Aβ clearance compared to ApoE3, and
increases amyloid formation in the brain [4]. Brain plaque load is the lowest in ApoE2 and
the highest in ApoE4 individuals [2]. More recent research, however, is focusing on diverse
roles for ApoE in the brain as a mediator of cerebrovascular function, neuroinflammation,
synapse formation, and neurotoxicity [2].
A clear role for ApoE in the modulation of the innate immune system has been iden-
tified. Neuroinflammation is known to play a key role in the pathological progression
of AD [5–7], and ApoE4 is associated with pro-inflammatory changes in both the central
nervous system (CNS) and periphery [8]. Post-mortem ApoE4-expressing brain samples ex-
hibit upregulation in proteins related to the regulation of inflammatory response, compared
to both ApoE3 and ApoE2-expressing tissue [9]. Specifically, a clear role for mediating
microglia phenotype and function has been identified for ApoE. Microglia expressing
human ApoE4 exhibit significantly increased production of pro-inflammatory mediators,
including tumor necrosis factor-α (TNFα), interleukin (IL)-6, and nitric oxide (NO) [10–13].
More recent research using iPSC-derived microglia expressing human ApoE found that
ApoE4 microglia have impaired migration and reduced phagocytic function [14]. Further
support for the ability of ApoE to regulate neuroinflammatory processes comes from the
finding that ApoE signaling via triggering receptor expressed on myeloid cells 2 (TREM2)
regulates a switch in microglia towards a neurodegenerative phenotype. Targeting ApoE
signaling has the ability to restore homeostatic function in microglia [15]. Therefore, ApoE
modulation of the innate immune system, particularly through alterations in microglia
phenotype, may play a key role in ApoE-related AD pathology.
ApoE isoforms may also regulate neuronal survival or toxicity, a key aspect of neu-
rodegenerative pathological processes in AD. Directly, treatment of iPSC-derived neurons
with recombinant ApoE2/3/4 stimulates various signal transduction cascades with differ-
ent levels of potency. One such cascade is APP synthesis and synapse formation, which is
enhanced in ApoE4 treated neurons and reduced in ApoE2 treated compared to ApoE3 [16].
ApoE4 has been shown to promote tau phosphorylation and neurotoxicity [2], as well as
impair synaptogenesis [3]. ApoE4 is more susceptible than other isoforms to proteolytic
cleavage, and this cleavage fragment is neurotoxic [17]. Indirectly, ApoE may influence
synapse formation and neuron survival through astrocyte activity. ApoE3 enhances astro-
cyte phagocytosis of synapses, while ApoE4 decreases the same activity [18]. Astrocytes
are also a primary producer of neurotrophic support, including brain derived neurotrophic
factor (BDNF). BDNF is decreased in the serum and brain of AD patients compared to
healthy controls [19,20], and ApoE isoforms have been found to modulate astrocyte pro-
duction and secretion of BDNF [21]. Overall, these findings further indicate that ApoE
isoform-specific effects on cells in the brain, including neurons and astrocytes, may be
responsible for the increased ApoE4-related AD risk.
The goal of this study was to better understand how the ApoE isoforms (ApoE2/3/4)
confer differential AD-related risk by assessing cell-specific ApoE-related neuroinflam-
matory and neurotoxic effects. Human microglia, astrocytes, and neurons were treated
with ApoE2/3/4 in vitro, and the effects of the ApoE isoforms on markers related to neu-
roinflammation and neurotoxicity were assessed. Our findings help to better characterize
the isoform and cell-specific effects of ApoE that may contribute to the development of
AD-related inflammation and neuron death.
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2. Materials and Methods
2.1. Cells and Other Reagents
Human immortalized microglia cell line (HMC3; CRL-3304) and Eagle’s Minimum
Essential Medium (EMEM; 30-2003) were purchased from ATCC (Manassas, VA, USA).
Human primary astrocytes (#1800) and astrocyte medium (#1801) along with astrocyte
growth supplements were purchased from ScienCell Research Laboratories (Carlsbad, CA,
USA). Human neuroblastoma cells (SH-SY5Y) were kindly provided by Dr. Navindra
Seeram (University of Rhode Island, Kingston, RI, USA). Dulbecco’s Modified Eagle
medium (DMEM), DMEM/F12, fetal bovine serum (FBS), bovine serum albumin (BSA),
poly-L-lysine, and recombinant human ApoE2 (rh-ApoE2), ApoE3 (rh-ApoE3), and ApoE4
(rh-ApoE4) were purchased from Sigma Aldrich (St. Louis, MO, USA).
2.2. Cell Culture and Treatments
HMC3 were grown and maintained in EMEM with 10% FBS. Treatment media was
serum free EMEM. Human primary astrocytes were plated on poly-L-lysine coated plates
and maintained in astrocyte medium with growth supplements and 2%FBS, according
to protocols provided by ScienCell. For treatments, media was replaced with serum-
free DMEM. SH-SY5Y were grown and maintained in DMEM/F12 with 10% FBS, and
treatments were done in serum-free DMEM/F12.
Rh-ApoE2/3/4 were dissolved in PBS pH 7.4 to make a stock at 6 µM. All cells were
treated with cholesterol (100 µM) (control) with or without 20 nM rh-ApoE2/3/4 for 24 h.
ApoE and cholesterol were added separately to cultures. The concentration of ApoE
was selected based on previous results with both human astrocytes and SH-SY5Y [21,22].
Cholesterol was utilized for these experiments because evidence suggests the effects of
ApoE isoforms are determined by their lipidation state [23].
2.3. Cell Viability and Toxicity
The viability of SH-SY5Y was assessed following treatments with rh-ApoE2/3/4.
Cells were seeded in 96-well plates at 100,000 cells/mL, and were allowed to adhere for
48 h. Cells were treated with cholesterol with or without rh-ApoE2/3/4 for 24 h. Cellular
viability was determined as a percentage of control (cholesterol) by CellTiter 96 ® Aqueous
One Solution Cell Proliferation Assay (MTS; Promega, Madison, WI, USA), and read
for absorbance at 490 nm on the Synergy HTX multi-mode reader (Biotex Instruments,
Winooski, VT, USA).
Cellular toxicity of SH-SY5Y following treatments was assessed by measuring lac-
tate dehydrogenase (LDH) release in the conditioned media. Supernatant from cells was
collected and total LDH was assessed using a cytotoxicity detection kit (Millipore Sigma,
Burlington, MA, USA). Samples were incubated with chromogenic dye and catalyst, then
absorbance was read at 490 nm using a Synergy HTX multi-mode reader (Biotek Instru-
ments, Winooski, VT, USA).
2.4. Western Blot
Western blot was used to measure protein expression in astrocytes and microglia
following treatment with rh-ApoE2/3/4. Cellular protein was extracted as previously
described [24]. Briefly, cells were lysed in Tris-HCl buffer with protease inhibitors. Lysates
were mixed with Sample Buffer (BioRad, Hercules, CA, USA) and samples were run by SDS-
PAGE on gradient gels (Invitrogen, Carlsbad, CA, USA). For all Western blots, 25 µg total
protein was loaded for each well. Samples were transferred to nitrocellulose membranes
(iBlot, Invitrogen, Carlsbad, CA, USA). All membranes were blocked and incubated with
primary antibody overnight at 4 ◦C. For BDNF Western blots, secreted media was collected
from treated astrocytes and concentrated 10-fold as previously described [21]. Samples
were run using the same method as outlined above, with 40 µg of total protein loaded for
each well. Primary antibodies include IL-6 (Bioss, Woburn, MA, USA; bs-4539R; 1:500),
TNFα (Novus Biologicals, Littleton, CO, USA; NBP1-19532; 1:500), IL-1β (Bioss, Woburn,
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MA, USA; bs-6319R; 1:1000), TREM2 (Novus Biologicals, Littleton CO, USA; NBP1-07101;
1:500), Clec7a (Novus Biologicals, Littleton, CO, USA; NB01-45514; 1:500), BDNF (Abcam,
Cambridge, MA, USA; ab108319; 1:1000), and β-Actin (Santa Cruz, Dallas, TX, USA; AC-15;
1:10,000). Bound antibody was detected by infrared secondary antibodies (Li-COR, Lincoln,
NE, USA; 1:10,000), and imaged on LiCor Odyssey (Li-COR Biosciences, Lincoln, NE, USA).
Quantification of Western blots was done in ImageJ, and values for each protein were
normalized to β-Actin on the same blot.
2.5. Statistical Analysis
All data were analyzed for significance using one-way analysis of variance (ANOVA)
and multiple comparisons post-hoc were completed using Bonferroni test on GraphPad
Prism (version 8.04; GraphPad, San Diego, CA, USA). Data are represented as Mean ± SEM,
groups contain N = 3 unless otherwise specified. Statistical significance was set at p ≤ 0.05
for all experiments.
3. Results
3.1. ApoE4 Increases Inflammatory Cytokine Expression in Human Astrocytes
ApoE4 is associated with increased inflammation in various model systems and
disease states [8,25,26]. Recently, the regulation of cholesterol by ApoE4 in the brain has
been shown to be cell-type specific [27]. While astrocytes have been widely studied for their
role in ApoE4-related lipid homeostasis and glucose metabolism [28], less is known about
their function in ApoE4-associated neuroinflammation. Here we explored the ability of
ApoE isoforms to affect the production of pro-inflammatory cytokines in human astrocytes.
Intracellular expression of inflammatory cytokines IL-1β (Figure 1A), TNFα (Figure 1B),
and IL-6 (Figure 1C) in human astrocytes following treatment with rh-ApoE2/3/4 was eval-
uated by Western blot. Treatment of astrocytes with all three ApoE isoforms significantly
(p < 0.001) increased IL-1β expression compared to control cells (Figure 1A). However,
ApoE4 evoked the highest level of IL-1β, which was significantly higher than that observed
with ApoE 2 (p < 0.01). ApoE2 and ApoE3 both appeared to elicit a small but not significant
increase in TNFα. In contrast, ApoE4 significantly (p < 0.05) increased TNFα compared
to control, as well as to ApoE2 (Figure 1B). The ability of ApoE isoforms to affect IL-6
expression followed a pattern similar to that observed for IL-1β. Treatment of astrocytes
with all three ApoE isoforms significantly (p < 0.01) increased IL-6 expression compared
to untreated control cells (Figure 1C). However, ApoE4 evoked the highest level of IL-6,
which was significantly (p < 0.05) higher than that observed with either ApoE2 or ApoE3.
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Figure 1. Expression of inflammatory cytokines by astrocytes treated with ApoE isoforms. Human
primary astrocytes were grown in vitro and treated for 24 h with 100 µM cholesterol (control) with or
without recombinant ApoE2/3/4 (20 nM). Following treatment, cell lysate was collected and Western
blot was used to assess the expression of inflammation-related proteins: (A) IL-1β, (B) TNFα, and
(C) IL-6. N = 3, * p < 0.05 vs. Control, ** p < 0.01 vs. Control, *** p < 0.001 vs. Control, # p < 0.05 vs.
ApoE3, ^ p < 0.05 vs. ApoE2, ^^ p < 0.01 vs. ApoE2.
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3.2. ApoE4 Enhances the Inflammatory Activation of Microglia
Microglia exhibit a range of phenotypes and activation states in response to extra-
cellular signals. We examined the effect of treatment with ApoE isoforms on the human
microglial cell line HMC3. Western blot was used to measure the expression of cytokines
and markers related to inflammation (Figure 2) and microglial activation (Figure 3).
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DNF was significantly (p < 0.001) elevated in ApoE3 treated cells compared to control, 
ApoE2, and ApoE4 groups. ProBDNF expression was also significantly (p < 0.01) elevated 
in ApoE4 treated cells compared to control. ApoE2 treatment did not alter the secretion of 
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significantly (p < 0.001) increased the level of mature BDNF detected in the secreted media 
(Figure 4). ApoE3 appeared to slightly increase mature BDNF secretion, although to a sig-
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on release of mature BDNF, with levels again undetectable (Figure 4B). 
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We examined the effect of ApoE isoforms on the production of both the pro-inflammatory
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properties. Treatment with ApoE4 increases TNFα level (ApoE2 vs. ApoE4 p = 0.0915;
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Microglia have been shown to take on an alternate activation state in AD, termed
disease-associated microglia (DAM) [15,29]. DAMs are characterized by decreased ex-
pression of homeostatic markers and increased expression of a sub-set of inflammatory
indicators. HMC3 were treated as described above and Western blot was used to assess the
expression of markers related to microglia activation, TREM2 and Clec7a (Figure 3A,B). The
data showed that treatment with either ApoE2 or ApoE3 diminished expression of TREM2
and Clec7a compared to control, while ApoE4 exposure increased levels of both TREM2
(Figure 3A) and Clec7a (Figure 2B). Expression of both TREM2 and Clec7a was significantly
(p < 0.05) elevated in the ApoE4 treated group compared to ApoE3. Expression levels for
TREM2 and Clec7a were also increased compared to ApoE2, though the difference was
not significant (p = 0.1043 and p = 0.257, respectively). Both TREM2 and Clec7a expression
levels were unchanged compared to control (Figure 3A,B).
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media (Figure 4). ApoE3 appeared to slightly increase mature BDNF secretion, although to
a significantly (p < 0.05) lower extent than ApoE2. Exposure of astrocytes to ApoE4 had no
effect on release of mature BDNF, with levels again undetectable (Figure 4B).
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on release of m ture BDNF, with levels again undetectable (Figure 4B). 
 
Figure 4. Evaluation of neurotrophic factors following treatment with ApoE isoforms. Human
primary astrocytes were grown in vitro and treated for 24 h with 100 µM cholesterol (control)
with or without recombinant ApoE2/3/4 (20 nM). Following treatment, astrocyte supernatant was
collected, concentrated 10-fold, and Western blot was used to assess the expression of secreted
BDNF. Expression was evaluated for both the (A) proBDNF and (B) mature BDNF isoforms. N = 3,
** p < 0.01 vs. Control, *** p < 0.001 vs. Control, ### p < 0.001 vs. ApoE3, ^ p < 0.05 vs. ApoE2,
^^^ p < 0.001 vs. ApoE2.
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To further investigate the potential neuroprotective and neurotoxic effects of ApoE
isoforms, we directly exposed the neuronal cell line SH-SY5Y to rh-ApoE2/3/4 for 24 h and
assessed cellular viability (Table 1). Cellular viability was significantly (p < 0.01) increased
in ApoE2 treated SH-SY5Y compared to control, with an increase of 14.9% ± 0.663. Viability
was significantly (p < 0.001) decreased in ApoE4 compared to both ApoE2 and ApoE3,
with a decrease of 9.7% ± 4.202 compared to control (Table 1). SH-SY5Y cells exposed to
ApoE isoforms were also analyzed for cellular toxicity. Neither ApoE2 nor ApoE3 had
any effect on release of lactate dehydrogenase (LDH). In contrast, ApoE4 treated cells
display significantly (p < 0.05) increased cytotoxicity compared to untreated controls, with
an increase in LDH release of 14% ± 4.164 (Table 1). Together, these findings indicate
that ApoE2 is neuroprotective through both increased BDNF and direct action on neurons,
while ApoE4 is likely neurotoxic through both direct and indirect mechanisms.
Table 1. |SH-SY5Y viability and toxicity following treatment with ApoE2/3/4 in vitro. Human
neuroblastoma cell line (SH-SY5Y) was grown in vitro and treated for 24 h with 100 µM cholesterol
(control) with or without recombinant ApoE2/3/4 (20 nM). Following treatment, cellular viability
was measured using MTS and cellular release of lactate dehydrogenase (LDH) was assessed as a
measure of cellular toxicity. Data are represented as percent change versus control Mean ± SEM,
N = 3, * p < 0.05 vs. Control, ** p < 0.01 vs. Control, ^^^ p < 0.001 vs. ApoE2, ### p < 0.001 vs. ApoE3.
Treatment Group ApoE2 ApoE3 ApoE4
Cellular Viability (MTS) +14.9 ± 0.663 ** +9.7 ± 2.780 −9.7 ± 4.202 ^^^,###
Cellular Toxicity (LDH) +2.6 ± 3.046 +2.7 ± 4.156 +14 ± 4.164 *
4. Discussion
ApoE4 is the strongest known genetic risk factor for late-onset AD, while ApoE2
appears to be protective. While the different levels of risk related to each isoform have
been well-established, the mechanism responsible for this relationship is still not entirely
understood. Here, we investigated the cell type-specific effects of ApoE2/3/4 in the brain
on markers related to neuroinflammation and neurotoxicity. Our results showed that ApoE
acts in an isoform-specific manner to modulate pro-inflammatory activity of microglia and
astrocytes, and affects neuron survival through both direct and indirect mechanisms.
We investigated the expression of pro-inflammatory cytokines by both microglia and
astrocytes following treatment with ApoE isoforms. ApoE4 treatment increased the produc-
tion of TNFα in relation to both ApoE2 and ApoE3, but significantly reduced the expression
of IL-6 in microglia. While the pro-inflammatory activation of microglia by ApoE4 had
been well-established, less is known about the ApoE-related inflammatory effects in astro-
cytes. Astrocytes, like microglia, are key regulators of the brain’s inflammatory response,
and have been implicated in AD-related inflammatory and pathological processes [30].
Astrocytes have been found to produce inflammatory cytokines, including IL-6 and TNFα,
following traumatic injury and ischemia [31]. Here, we show that ApoE treatment signifi-
cantly increases the production of pro-inflammatory cytokines IL-1β, IL-6, and TNFα in
a dose-dependent manner, with ApoE2 representing the lowest cytokine expression and
ApoE4 representing the highest. TNFα is a key mediator in neuropathology and has been
found to promote excitotoxicity, synaptic loss, and exacerbated amyloidogenesis in AD.
Additionally, there is evidence to suggest elevated serum levels of TNFα in AD [32,33]. The
production of TNFα is increased in both activated microglia and astrocytes in response to
injury [32], and here TNFα expression is increased by ApoE4 in both cell types. Similar to
TNFα, IL-1β is a pleiotropic cytokine that amplifies immune reactions [34] and is elevated
in the CSF of AD patients [35]. Both TNFα and IL-1 can induce increased production of IL-6
and other inflammatory mediators via NF-κβ activation [33]. Mice with astrocyte-specific
enhanced IL-6 production exhibit neurodegeneration and demyelination, along with de-
creased hippocampal long-term potentiation and learning impairments. Microglia in these
mice also have enhanced pro-inflammatory activation [36]. However, IL-6 signaling is
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largely context dependent, and has been shown to mediate both pro-inflammatory and
anti-inflammatory, protective processes [37], which may in part help to explain the reduc-
tion in IL-6 production by ApoE4-treated microglia. These findings highlight a previously
underexplored role for ApoE in modulating the inflammatory state of astrocytes, and
suggest that ApoE4 may influence AD pathology via increased production of inflammatory
cytokines in both astrocytes and microglia.
These data also suggest ApoE-related differential activation of microglia. HMC3
microglia were treated with rh-ApoE2/3/4 and markers related microglial activation state
were assessed. DAM refers to a subset of microglia identified in the AD brain that have
dysregulated expression of sensing, house-keeping, and host-defense genes [15,29,38].
DAM are largely localized around Aβ plaques and display elevation of lipid metabolism
and phagocytic activity-related genes, as well as genes related to increased AD risk [15].
ApoE is known to play a key role in the phenotypic of switch of microglia through signaling
at TREM2 [15]. Here, we further the idea that ApoE4 enhances activation of the DAM
phenotype by showing that ApoE4 treatment increased the expression of both TREM2
and the downstream, DAM-related protein Clec7a. This suggests that ApoE4 may confer
increased risk for AD through increased activation of disease-associated microglia, and
related, down-stream pro-inflammatory and disease progressing effects. It is interesting to
note that expression of both TREM2 and Clec7a were not significantly different in ApoE4
treated cells when compared to control, suggesting that ApoE2 or ApoE3 may be acting in
a protective manner to lower the baseline expression of these proteins.
Finally, our findings support the idea that ApoE2 is neuroprotective while ApoE4
is neurotoxic through both direct and indirect mechanisms. Human neuroblastoma cells
(SH-SY5Y) were treated with rh-ApoE2/3/4 and cellular viability was assessed. ApoE2
significantly increased, while ApoE4 significantly decreased, viability. Synapse loss and
progressive neuron death are core pathological hallmarks of AD, and these losses correlate
with cognitive impairment [39]. Therefore, ApoE4 may help to promote AD pathological
progression by enhancing neuron death, while ApoE2 protects against these same processes.
Additionally, human astrocytes were treated with rh-ApoE2/3/4 and the secretion of the
neurotrophic factor BDNF and its pro-form was assessed. Secretion of growth factors,
including BDNF, is a major function of astrocytes [30]. BDNF has been found to be reduced
in human AD, and a previous study found that ApoE isoforms modulated astrocyte
production of specific BDNF isoforms [19–21]. Here, we show that ApoE2 significantly
increased astrocyte secretion of mature BDNF. Peripheral BDNF has been found to protect
against AD, with one standard deviation higher serum BDNF conferring a 33% decreased
risk for AD [40]. BDNF enhances neurogenesis and neurotransmission, promotes synaptic
growth and plasticity, and increases hippocampal long-term potentiation and related
memory formation [19]. Additionally, BDNF has been found to have anti-apoptotic and
anti-oxidant functions in experimental models of neurodegenerative disease [41]. On
the other hand, both ApoE3 and ApoE4 exhibited an increased secretion of the proBDNF
isoform. We have previously reported similar findings, suggesting that ApoE2 may enhance
the cleavage of proBDNF to the mature form [21]. Unlike mature BDNF, proBDNF has been
linked with the promotion of long-term depression and cell death [42]. Taken together,
these findings support the hypothesis that ApoE2 reduces risk for AD by acting in a
neuroprotective manner, through both direct and indirect action at neurons. On the
other hand, ApoE4 may further promote AD-related risk through its neurotoxic effects in
the brain.
While our findings support a pro-inflammatory and neurotoxic role for ApoE4, along
with a neuroprotective one for ApoE2, it is important to interpret these results with
a degree of caution. These data represent a relatively small sample size (n = 3) in a
simplified in vitro system. While this system is advantageous in that it allows for the
assessment of cell-specific ApoE-related effects, it is likely that ApoE-related mechanisms
are more complicated in a complex in vivo system in which these (and other) cell types can
communicate with each other. Newer models may help to better model this intracellular
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communication in vitro [43]. Additionally, immortalized cell lines were utilized for both
microglia and neurons, and these responses may not perfectly mirror that of primary cells.
Therefore, these findings should be interpreted as preliminary, and further investigation
should be conducted to more clearly characterize the cell- and isoform-specific effects
of ApoE in the brain. Such further studies may also help to further characterize the
therapeutic potential of targeting ApoE signaling at various cell types. Recent studies have
highlighted the therapeutic potential of targeting ApoE4, with one such study finding
that ApoE immunotherapy was able to ameliorate amyloid-related pathology and protect
cerebrovascular function in a mouse model of AD [44].
5. Conclusions
Overall, our findings highlight that ApoE acts as a multi-functional mediator in
AD-related pathological processes. In an isoform-specific manner, ApoE regulates neuroin-
flammation and neurotoxicity through direct actions on microglia, astrocytes, and neurons.
In general, ApoE4 promotes pro-inflammatory and neurotoxic processes, while ApoE2
acts in a neuroprotective manner, highlighting the differential risk associated with these
ApoE isoforms in the development of AD. Additionally, these findings suggest that target-
ing ApoE-related signaling may be potential therapeutic strategy for mitigating multiple
AD-related pathological processes in individuals who carry the ApoE4 allele.
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